Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Medulloblastoma is heterogeneous, being characterized by molecular subgroups that demonstrate distinct gene expression profiles. Activation of the WNT or SHH signaling pathway characterizes two of these molecular subgroups, the former associated with low-risk disease and the latter potentially targeted by novel SHH pathway inhibitors. This manuscript reports the validation of a novel diagnostic immunohistochemical method to distinguish SHH, WNT, and non-SHH/WNT tumors and details their associations with clinical, pathological and cytogenetic variables. A cohort (n = 235) of medulloblastomas from patients aged 0.4–52 years was studied for expression of four immunohistochemical markers: GAB1, β-catenin, filamin A, and YAP1. Immunoreactivity (IR) for GAB1 characterizes only SHH tumors and nuclear IR for β-catenin only WNT tumors. IRs for filamin A and YAP1 identify SHH and WNT tumors. SHH, WNT, and non-SHH/WNT tumors contributed 31, 14, and 55% to the series. All desmoplastic/nodular (D/N) medulloblastomas were SHH tumors, while most WNT tumors (94%) had a classic phenotype. Monosomy 6 was strongly associated with WNT tumors, while PTCH1 loss occurred almost exclusively among SHH tumors. MYC or MYCN amplification and chromosome 17 imbalance occurred predominantly among non-SHH/WNT tumors. Among patients aged 3–16 years and entered onto the SIOP PNET3 trial, outcome was significantly better for children with WNT tumors, when compared to SHH or non-SHH/WNT tumors, which showed similar survival curves. However, high-risk factors (M+ disease, LC/A pathology, MYC amplification) significantly influenced survival in both SHH and non-SHH/WNT groups. We describe a robust method for detecting SHH, WNT, and non-SHH/WNT molecular subgroups in formalin-fixed medulloblastoma samples. In corroborating other studies that indicate the value of combining clinical, pathological, and molecular variables in therapeutic stratification schemes for medulloblastoma, we also provide the first outcome data based on a clinical trial cohort and novel data on how molecular subgroups are distributed across the range of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
International Agency for Research on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,435
Altered Neural Cell Fates and Medulloblastoma in Mouse patched Mutants
Goodrich, L. V., Milenković, L., Higgins, K. M., & Scott, M. P. (1997) · Science · doi:10.1126/science.277.5329.1109 · Cited by 1,696 · cited 1×
“Activation of the SHH pathway, which stimulates proliferation of granule cell neurons during cerebellar development, has been used to create mouse models of medulloblastoma [21, 46].”
BackgroundMedulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,339
Self-citationTreatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,019
Gajjar, A., Chintagumpala, M., Ashley, D., Kellie, S., Kun, L. E., Merchant, T. E., Woo, S., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Self-citationSubtypes of medulloblastoma have distinct developmental origins
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., Kranenburg, T. A., Hogg, T., Poppleton, H., Martin, J., et al. (2010) · Nature · doi:10.1038/nature09587 · Cited by 831
Self-citationMutations in SUFU predispose to medulloblastoma
Taylor, M. D., Liu, L., Raffel, C., Hui, C.-C., Mainprize, T. G., Zhang, X., Agatep, R., Chiappa, S., Gao, L., Lowrance, A., et al. (2002) · Nature Genetics · doi:10.1038/ng916 · Cited by 806
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone
Rutkowski, S., Bode, U., Deinlein, F., Ottensmeier, H., Warmuth-Metz, M., Soerensen, N., Graf, N., Emser, A., Pietsch, T., Wolff, J. E. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042176 · Cited by 751
Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S.-V., Caron, H. N., Cloos, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003088 · Cited by 722
Self-citationCho, Y.-J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5148 · Cited by 717
Self-citationGenomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations
Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., Chintagumpala, M., Adesina, A., Ashley, D. M., Kellie, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4974 · Cited by 668
Self-citationSporadic medulloblastomas contain PTCH mutations.
Raffel, C., Jenkins, R. B., Frederick, L. A., Hebrink, D. M., Alderete, B. E., Fults, D. W., & James, C. D. (1997) · PubMed · Cited by 570
Ellison, D. W., Onilude, O. E., Lindsey, J. C., Lusher, M. E., Weston, C. L., Taylor, R. E., Pearson, A. D., & Clifford, S. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5479 · Cited by 435
Self-citationREIFENBERGER, J., Wolter, M., Weber, R. G., Megahed, M., Ruzicka, T., Lichter, P., & Reifenberger, G. (1998) · PubMed · Cited by 426
Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.
Wetmore, C., Eberhart, D. E., & Curran, T. (2001) · PubMed · Cited by 390
Sporadic medulloblastomas contain oncogenic beta-catenin mutations.
Zurawel, R. H., CHIAPPA, S. A., Allen, C., & Raffel, C. (1998) · PubMed · Cited by 387
Fernandez-L, A., Northcott, P. A., Dalton, J., Fraga, C., Ellison, D., Angers, S., Taylor, M. D., & Kenney, A. M. (2009) · Genes & Development · doi:10.1101/gad.1824509 · Cited by 377
Self-citationPietsch, T., Waha, A., Koch, A., Kraus, J., Albrecht, S., Tonn, J. C., Sörensen, N., Berthold, F., Henk, B., Schmandt, N., et al. (1997) · PubMed · Cited by 373
Taylor, R. E., Bailey, C. C., Robinson, K., Weston, C. L., Ellison, D., Ironside, J., Lucraft, H., Gilbertson, R., Tait, D. M., Walker, D. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.116 · Cited by 353
Self-citationSurvival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis
Rutkowski, S., von Hoff, K., Emser, A., Zwiener, I., Pietsch, T., Figarella-Branger, D., Giangaspero, F., Ellison, D. W., Garre, M.-L., Biassoni, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2299 · Cited by 323
Self-citationFilamins in cell signaling, transcription and organ development
Zhou, A.-X., Hartwig, J. H., & Akyürek, L. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.12.001 · Cited by 319
Ellison, D. W., Kocak, M., Dalton, J., Megahed, H., Lusher, M. E., Ryan, S. L., Zhao, W., Nicholson, S. L., Taylor, R. E., Bailey, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2810 · Cited by 302
Self-citationThe Origins of Medulloblastoma Subtypes
Gilbertson, R. J., & Ellison, D. W. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151518 · Cited by 294
Self-citationPfister, S., Remke, M., Benner, A., Mendrzyk, F., Toedt, G., Felsberg, J., Wittmann, A., Devens, F., Gerber, N. U., Joos, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9432 · Cited by 293
APC Mutations in Sporadic Medulloblastomas
Huang, H., Mahler-Araujo, B. M., Sankila, A., Chimelli, L., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64747-5 · Cited by 280
Clifford, S. C., Lusher, M. E., Lindsey, J. C., Langdon, J. A., Gilbertson, R. J., Straughton, D., & Ellison, D. W. (2006) · Cell Cycle · doi:10.4161/cc.5.22.3446 · Cited by 270
Self-citationNishida, K., Yoshida, Y., Itoh, M., Fukada, T., Ohtani, T., Shirogane, T., Atsumi, T., Takahashi-Tezuka, M., Ishihara, K., Hibi, M., et al. (1999) · Blood · doi:10.1182/blood.v93.6.1809.406k35_1809_1816 · Cited by 239
Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas.
Dahmen, R. P., Koch, A., Denkhaus, D., Tonn, J.-C., Sörensen, N., Berthold, F., Behrens, J., Birchmeier, W., Wiestler, O. D., & Pietsch, T. (2001) · PubMed · Cited by 216
Kimura, H., Ng, J. M. Y., & Curran, T. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.027 · Cited by 212
Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients
Lamont, J. M., McManamy, C. S., Pearson, A. D., Clifford, S. C., & Ellison, D. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0721 · Cited by 209
Self-citationMedulloblastoma with extensive nodularity: a variant with favorable prognosis
Giangaspero, F., Perilongo, G., Fondelli, M. P., Brisigotti, M., Carollo, C., Burnelli, R., Burger, P. C., & Garrè, M. L. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.91.6.0971 · Cited by 205
Kiyatkin, A., Aksamitiene, E., Markevich, N. I., Borisov, N. M., Hoek, J. B., & Kholodenko, B. N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600482200 · Cited by 195 · cited 1×
“GAB1 (GRB2-associated binding protein 1) is a member of the Gab/DOS (Daughter of Sevenless) family of adapter proteins and is involved in multiple cell processes, including morphogenesis, proliferation, and cell adhesion and motility [19, 24, 31].”
BackgroundFattet, S., Haberler, C., Legoix, P., Varlet, P., Lellouch‐Tubiana, A., Lair, S., Manie, E., Raquin, M., Bours, D., Carpentier, S., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2514 · Cited by 193
Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours
Vorechovský, I., Tingby, O., Hartman, M., Strömberg, B., Nister, M., Collins, V. P., & Toftgård, R. (1997) · Oncogene · doi:10.1038/sj.onc.1201340 · Cited by 192
Analysis ofPTCH/SMO/SHH pathway genes in medulloblastoma
Zurawel, R. H., Allen, C., CHIAPPA, S. A., Cato, W., Biegel, J. A., Cogen, P. H., de Sauvage, F. J., & Raffel, C. (2000) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(200001)27:1<44::aid-gcc6>3.0.co;2-v · Cited by 191
Zhong, Z., Yeow, W.-S., Zou, C., Wassell, R., Wang, C., Pestell, R. G., Quong, J. N., & Quong, A. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-08-1108 · Cited by 166
Somatic mutations ofWNT/wingless signaling pathway components in primitive neuroectodermal tumors
Koch, A., Waha, A., Tonn, J. C., S�rensen, N., Berthold, F., Wolter, M., Reifenberger, J., Hartmann, W., Friedl, W., Reifenberger, G., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1342 · Cited by 160
Giangaspero, F., Rigobello, L., Badiali, M., Loda, M. F., Andreini, L., Basso, G., Zorzi, F., & Montaldi, A. (1992) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199207000-00007 · Cited by 152
McManamy, C. S., Pears, J., Weston, C. L., Hanzely, Z., Ironside, J. W., Taylor, R. E., Grundy, R. G., Clifford, S. C., Ellison, D. W., & on behalf of the Clinical Brain Tumour Group, C. C. A. L. G. (. T. U. C. C. S. G. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00058.x · Cited by 146
Self-citationLarge-cell medulloblastomas. A distinct variant with highly aggressive behavior.
Giangaspero, F., Rigobello, L., Badiali, M., Loda, M. F., Andreini, L., Basso, G., Zorzi, F., & Montaldi, A. (1992) · PubMed · Cited by 143
Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease
Ellison, D. W. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0726-6 · Cited by 138
Self-citationPizer, B. L., & Clifford, S. C. (2009) · British Journal of Neurosurgery · doi:10.1080/02688690903121807 · Cited by 97
Self-citationKoch, A., Hrychyk, A., Hartmann, W., Waha, A., Mikeska, T., Waha, A., Schüller, U., Sörensen, N., Berthold, F., Goodyer, C. G., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22675 · Cited by 68
Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma
Al-Halabi, H., Nantel, A., Klekner, Á., Guiot, M. C., Albrecht, S., Hauser, P., Garami, M., Bognár, L., Kavan, P., Gerges, N., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0780-0 · Cited by 48
Gillgrass, A. E., Cardiff, R. D., Sharan, N., Kannan, S., & Muller, W. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206983 · Cited by 30
Cited by
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Self-citationThe 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Self-citationYAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
“…al., 2015b; Liu et al., 2013a) Medulloblastoma IHC and gene expression: YAP expression is elevated in the SHH and WNT subtypes of medulloblastoma (Ellison et al., 2011; Fernandez et al., 2009) YAP protein levels are upregulated in mouse models of medulloblastoma (Fernandez et al., 2009) YAP…”
BackgroundMolecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
“True nodular/desmoplastic tumors, and likely all of the MBENs belong to the Shh subgroup of tumors [11, 26].”
BackgroundSelf-citationTargeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., Yang, S. X., & Ivy, S. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.61 · Cited by 1,298
Metadata
- Authors
- Ellison, D. W., Dalton, J., Kocak, M., Nicholson, S. L., Fraga, C., Neale, G., Kenney, A. M., Brat, D. J., Perry, A., Yong, W. H., Taylor, R. E., Bailey, S., Clifford, S. C., & Gilbertson, R. J.
- Venue
- Acta Neuropathologica
- Published
- 2011-01-26
- Volume
- 121
- Issue
- 3
- Pages
- 381-396
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2045711626
- Cited by
- 563
- References
- 46
- FWCI
- 18.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.